Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 5:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Antidepressant Regimen Clear all
Completed Phase 1 Interventional Results available

Motivational Interviewing to Improve Medication Adherence Among Hispanic Adults With Depression

NCT00356304
View directory record Official record
Conditions
Depression
Interventions
Motivational interviewing, Treatment as usual
Behavioral
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Sep 27, 2026, 5:22 PM EDT
Recruiting Phase 4 Interventional

RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)

NCT07266545
View directory record Official record
Conditions
Unipolar Depression, Bipolar Depression
Interventions
Vortioxetine, Cariprazine (Augmentation Phase)
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 27, 2026, 5:22 PM EDT
Withdrawn Not applicable Interventional

Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive Disorder

NCT01613820
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Scopolamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 27, 2026, 5:22 PM EDT
Completed Phase 2 Interventional

Exercise Plus Duloxetine for Knee Osteoarthritis

NCT04111627
View directory record Official record
Conditions
Knee Osteoarthritis, Depression
Interventions
Aerobic exercise, Duloxetine
Behavioral · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
40 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 27, 2026, 5:22 PM EDT
Completed Phase 4 Interventional

Treatment of Depression in Adults

NCT00073697
View directory record Official record
Conditions
Depression
Interventions
Escitalopram, Interpersonal Psychotherapy, Escitalopram plus IPT
Drug · Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 66 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2012 · Synced Sep 27, 2026, 5:22 PM EDT
Completed No phase listed Observational

EEG Biomarkers for Predicting Response to Antidepressant Therapy

NCT00289523
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Not listed
Lead sponsor
Medtronic - MITG
Industry
Eligibility
21 Years to 75 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Sep 27, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 27, 2026, 5:22 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Magnetic Brain Stimulation for the Treatment of Adult Depression

NCT00149838
View directory record Official record
Conditions
Depression
Interventions
Prefrontal rTMS, Antidepressant Regimen, Sham Stimulation
Procedure · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 70 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
4
States / cities
Atlanta, Georgia • New York, New York • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2018 · Synced Sep 27, 2026, 5:22 PM EDT
Completed Phase 2 Interventional

Antidepressant Medication Plus Directly Observed Therapy for Improving Adherence to Antiretroviral Therapy

NCT00338767
View directory record Official record
Conditions
HIV Infections, Depression
Interventions
Directly Observed Therapy (DOT), Fluoxetine
Behavioral · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Sep 27, 2026, 5:22 PM EDT
Completed Not applicable Interventional Results available

Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder

NCT04076644
View directory record Official record
Conditions
MDD
Interventions
TMS treatment
Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 27, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression

NCT02493868
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
53
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 27, 2026, 5:22 PM EDT
Completed Not applicable Interventional

Effectiveness of Acupuncture for Depressed Patients Taking Antidepressant Medications

NCT01633996
View directory record Official record
Conditions
Depression
Interventions
Acupuncture
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2012 · Synced Sep 27, 2026, 5:22 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT02153502
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Bellflower, California • Costa Mesa, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 27, 2026, 5:22 PM EDT
Terminated Phase 2 Interventional Results available

Salicylic Augmentation in Depression

NCT03152409
View directory record Official record
Conditions
Depression, Depressive Disorder, Major Depressive Disorder, Treatment Resistant Depression
Interventions
Aspirin 325mg, Placebo Oral Tablet
Drug
Lead sponsor
Jessica Harder
Other
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 27, 2026, 5:22 PM EDT
Completed Not applicable Interventional Results available

Ketamine Infusion for Treatment-resistant Major Depressive Disorder

NCT01582945
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 27, 2026, 5:22 PM EDT
Completed Not applicable Interventional Results available

Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder

NCT01667926
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 27, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression

NCT02497287
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine (Intranasal Spray), Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
16
States / cities
New Haven, Connecticut • Miami, Florida • Marietta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 27, 2026, 5:22 PM EDT
Terminated Not applicable Interventional Results available

Tapering Off Antidepressants

NCT02661828
View directory record Official record
Conditions
Major Depressive Disorder, Anxiety Disorder, Obsessive Compulsive Disorder, Post-Traumatic Stress Disorder
Interventions
Two-Week Antidepressant Taper Regimen, One-Week Antidepressant Taper Regimen
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Sep 27, 2026, 5:22 PM EDT
Terminated Not applicable Interventional Results available

Cysteamine Therapy for Major Depressive Disorder

NCT00715559
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
cysteamine bitartrate
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 27, 2026, 5:22 PM EDT
Completed Not applicable Interventional Results available

Efficacy and Feasibility of a Personalized Treatment for Depression With Co-Occurring Anxiety

NCT00930293
View directory record Official record
Conditions
Depression, Anxiety
Interventions
Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS), Brief Supportive Psychotherapy (BSP), Citalopram hydrobromide
Behavioral · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Sep 27, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT03434041
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 27, 2026, 5:22 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Endeavor to Stop Nausea/Vomiting Associated With Pregnancy (E-SNAP)

NCT05452174
View directory record Official record
Conditions
Pregnancy, Severe Nausea and Vomiting, Hyperemesis Gravidarum
Interventions
Mirtazapine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 49 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 27, 2026, 5:22 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02418585
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • San Rafael, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 27, 2026, 5:22 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

Partner-Assisted Interpersonal Psychotherapy or Antidepressant Medication for Antenatal Depression

NCT01732055
View directory record Official record
Conditions
Partner Assisted Interpersonal Psychotherapy, Treatment as Usual
Interventions
Partner-Assisted Interpersonal Psychotherapy, Treatment as Usual
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Sep 27, 2026, 5:22 PM EDT